We evaluated a new commercial enzyme immunoassay (EIA) for rotavirus (Rotavirus EIA; International Diagnostic Laboratories, Chesterfield, Mo.). A total of 161 consecutive stool samples (including 18 from infants less than 30 days old) submitted to the diagnostic laboratory at Children's Hospital, Washington University Medical Center, St. Louis, Mo., for rotavirus detection were tested by Rotavirus EIA and by Rotazyme II (Abbott Laboratories, North Chicago, 111.) according to the instructions of the manufacturer. In addition, 16 samples from infants less than 30 days old without diarrhea were tested by both assays. Samples showing discrepant results after repeat testing were examined by electron microscopy. Nine samples yielding discrepant results were also tested by using a reference EIA directly on the specimen and on culture supernatants from two passages in MA 104 cells. Rotavirus EIA and Rotazyme Il yielded concordant results for 85% of the samples. All of the 26 discrepant samples tested negative by Rotavirus EIA and positive (15 samples) or equivocal (11 samples) by Rotazyme II. These samples included 11 from symptomatic infants more than 30 days old, 2 from symptomatic infants less than 30 days old (neonates), and 2 from neonates without diarrhea. Rotavirus was not detected in any of the 24 that were examined by electron microscopy or in any of the 9 that were tested by the reference EIA. The sensitivity, specificity, positive predictive value, and negative predictive value were 100% for Rotazyme EIA and 100, 90, 70, and 100%, respectively, for Rotazyme Il. Rotavirus EIA was comparable to Rotazyme Il in ease of performance. We conclude that Rotavirus EIA is equally sensitive and more specific than Rotazyme Il for detecting rotavirus. Rotavirus EIA is a practical and accurate rotavirus assay for use in clinical laboratories.
Human rotavirus is an important cause of diarrhea in young children (8) . The diagnosis of rotavirus infection has been greatly facilitated by the development and widespread application of enzyme immunoassay (EIA) techniques (2) . In the present study, we evaluated the performance of a new commercial EIA (Rotavirus EIA; International Diagnostic Laboratories, Chesterfield, Mo.) for rotavirus by comparing it with another widely used commercial EIA (Rotazyme II; Abbott Laboratories, North Chicago, Ill.). Samples yielding discrepant results were evaluated by electron microscopy. In addition, a subgroup of these samples was also tested by a reference EIA (Dakopatts, Glostrup, Denmark), both directly and after two passages in MA 104 cells (7) .
MATERIALS AND METHODS
Specimens. Specimens included in the study consisted of 161 consecutive stool samples (including 18 from infants less than 30 days old) submitted to the diagnostic laboratory at Children's Hospital, Washington University Medical Center, St. Louis, Mo., for rotavirus detection during the winters of 1984 to 1985 and 1985 to 1986 . In addition, 16 stool samples were obtained from infants less than 30 days old without diarrhea who were being cared for in the hospital's neonatal intensive care unit during the winter of 1985 to 1986. All specimens were refrigerated overnight or frozen for several days at -20°C before testing. * Corresponding author.
Assays. Rotavirus EIA uses a microtiter plate in which alternate wells are precoated with rabbit rotavirus antibody and preimmune rabbit serum. The assay was performed precisely according to directions of the manufacturer. Liquid stools were tested undiluted, and semiformed stools were diluted to approximately 1:5 with distilled water to reach a consistency suitable for pipette usage and then vortexed. Twenty microliters of the diluted sample was then added to each of two adjacent wells: one was coated with antirotavirus antibody, and the other was coated with preimmune serum. The plate was incubated at room temperature for 60 min. The contents of the wells were aspirated, and the wells were washed three times with wash solution. Fifty microliters of biotin-conjugated anti-rotavirus antibody was added to each well, followed immediately by 50 ,ul of avidin-horseradish peroxidase conjugate. The plate was incubated at room temperature for 30 min. After this incubation, the wells were washed four times, and 100 ,ul of ortho-phenylenediamine substrate was added. After 15 min of incubation at room temperature, the reaction was stopped by adding 100 ,ul of stop solution (1 M H2SO4). All tests were read visually and spectrophotometrically at 492 nm. Tests were considered positive by visual examination when the color in the test well was distinctly more intense than the color in the negative control well and spectrophotometrically if the difference between the A492 of the test well and that of the negative control well was >0.1 and if the A492 of the test well was at least six times that of the negative control well.
All samples were also tested by using the Rotazyme Il EIA (Abbott Laboratories, North Chicago, 111.). The 2360 CROMIEN ET AL.
Rotazyme Il assays were carried out precisely according to the instructions of the manufacturer. Each sample was diluted to an approximate 10% suspension with the speciment diluent supplied by the manufacturer. An antibodycoated bead was added to 200 ul of the sample in a reaction tray and incubated in a 37°C water bath for 60 min. After three washes with distilled water, 200 ,ul of horseradish peroxidase enzyme conjugate was added. The tray was again incubated in a 37°C water bath for 60 min. The bead was then washed three times with distilled water and transferred to a plastic test tube to which 300 ,ul of ortho-phenylenediamine substrate was added. After a 30-min incubation at room temperature, 1 ml of sulfuric acid was added to each tube to stop the reaction. The tube was then vortexed, and the A492 was read on a Quantum spectrophotometer. The cutoff value was determined by adding 0.075 to the A492 of the sample diluent control. A sample was considered positive if its A492 was more than 10% greater than the cutoff. A sample was considered negative if its A492 value was more than 10% below the cutoff. Samples with an A492 within 10% of the cutoff were considered equivocal.
Discrepant samples. All samples yielding discrepant results were retested by both assays. In all cases, the result of the second test was used for calculations. Most samples with persistent discrepancies were prepared for electron microscopy. In addition, nine discrepant samples and one sample that was positive by both assays were evaluated for the presence of rotavirus by using a reference EIA (Dakopatts) and cultivation in MA 104 cells.
Electron microscopy. Electron microscopy was performed by Grady W. Phillips, Jr., Department of Genetics, Washington University School of Medicine. Samples tested were diluted with water and centrifuged at a low speed to deposit particulate material. If the supernatant remained turbid, additional water was added, and the procedure was repeated until the supernatant was no longer turbid. Five microliters of the diluted sample was placed on fresh nitrocellulosecoated grids. After approximately 10 s, the excess was removed with filter paper, and 5 ,ul of 2% phosphotungstic acid (pH 7.2) was placed on the grid for approximately 10 s and then removed with filter paper. The preparation was then viewed with a Philips 201C transmission electron microscope for approximately 10 min per sample. All specimens that were initially negative for rotavirus were also examined by the pseudo-replica technique (4). Twenty-five microliters of the diluted stool sample was placed on a disk of 2% agar and allowed to dry. One drop of 1% nitrocellulose in amyl acetate was placed on the agar disk. The nitrocellulose membrane that formed was floated off in water and captured on a 300-mesh copper grid. One drop of 0.5% uranyl acetate was added and removed by filter paper after 10 s. The grid was then examined as described above.
Reference EIA. Nine discrepant samples and one positive sample were sent frozen to the laboratory of one of us (R.I.G.) for further testing, using an independent EIA (Dakopatts) and cultivation. Specimens were thawed, diluted 1:10 in veal infusion broth, and activated with trypsin (10 ,ug/ml) for 1 h at 37°C. Inocula were prepared by diluting the activated specimens 1:10 in Eagle minimal essential media containing glutamine (2 mM), chlortetracycline (25 ,ug/ml), penicillin (250 U/ml), amphotericin (2.5 ,ug/ml), and trypsin (0.5 pg/ml). These inocula (200 ,ul) were added to roller tubes of MA 104 cells that had been washed twice with the same material used to dilute the samples. The tubes were incubated on roller drums at 37°C for 1 h, washed with the diluent, refed, and returned to the roller drums for 7 to 10 days. At that time, material from each tube was passaged into an additional tube of MA 104 cells and incubated under similar conditions for an additional 10 days. After this passage, the supernatant was removed and tested by EIA.
Test parameters. To determine the sensitivity, specificity, and predictive values of both assays, each sample was classified as either true-positive or true-negative. Samples were considered true-positive if they were positive by both assays or if they were positive by one assay and by the confirmatory procedures (electron microscopy and, on selected samples, reference EIA). Samples were considered true-negative if they were negative by both assays or if they were negative by one assay and by the confirmatory procedures. The two samples that yielded discrepant results on the Rotavirus EIA and the Rotazyme II assays but which were not tested by the confirmatory procedures were excluded from this analysis. For each assay, the sensitivity was determined by dividing the number of true-positive samples by the number of true-positive plus false-negative samples. The specificity was determined by dividing the number of true-negative samples by the number of true-negative plus false-positive samples. The positive predictive value was determined by dividing the number of true-positive samples by the number of true-positive plus false-positive samples. The negative predictive value was determined by dividing the number of true-negative samples by the number of true-negative plus false-negative samples. In the calculations of the Rotazyme II test parameters, samples yielding equivocal results were included for the determination of sensitivity but were excluded from the determination of specificity.
RESULTS
This study included 143 samples from patients more than 30 days old. Of those samples, 30 (21%) were positive and 99 (69%) were negative by both assays ( 
DISCUSSION
In this study, we evaluated a new commercial EIA, Rotavirus EIA, that is designed to detect human rotavirus in stool samples. We found Rotavirus EIA to be equally sensitive and more specific than Rotazyme II, a widely used commercial EIA (1) . For all discrepancies that occurred in testing samples by both assays, Rotavirus EIA was negative and Rotazyme Il was either positive or equivocal.
Our belief that Rotavirus EIA is more specific than Rotazyme II rather than less sensitive is based on the results of independent tests to detect rotavirus in stool samples yielding discrepant results in the two assays. Electron microscopy did not reveal rotavirus in any of the 24 samples that were examined (of 26 samples that yielded discrepant results). Because some EIAs are more sensitive than direct electron microscopy for detecting rotavirus (6), we also used a reference EIA to test nine of the samples yielding discrep- 
